Navigation Links
Pepscan Achieves First Milestone in Research Collaboration With Genmab
Date:3/10/2009

LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics (Pepscan) today announced that it has earned a milestone payment from Genmab A/S. The milestone payment arises from an ongoing Research Collaboration aimed at identifying human antibodies against intractable targets. Pepscan is responsible for using it CLIPS(TM) technology to generate immunogens that mimic the protein targets to induce human antibodies against these intractable targets.

Under the terms of the collaboration agreement, Pepscan is eligible to receive additional payments from Genmab upon the achievement of certain development and regulatory milestones. Pepscan is also eligible to receive royalties on potential sales of any therapeutics developed as a result of the collaboration.

"The achievement of this milestone further validates Pepscan's CLIPS(TM) platform", said Rob Meloen, CSO of Pepscan Therapeutics. "We are pleased to see the significant progress that has been made in the collaboration with Genmab."

About Intractable Targets

"Intractable" Targets are drug targets that would be desirable to address with monoclonal antibodies but are inaccessible with alternative commercially available technologies. This can be due to the fact that target proteins are buried to a large extent very close to the cell surface or in the cell membrane or due to poor immunogenicity of the protein or desirable epitopes.

About Pepscan Therapeutics

Pepscan Therapeutics is a product focused immunotherapy company based in the Netherlands. It has developed a pipeline of therapeutic vaccine and antibody programs of which the most advanced is in Phase II clinical testing. Pepscan's proprietary and innovative CLIPS(TM) technology has proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs.

About CLIPS(TM) Technology

Chemicall
'/>"/>

SOURCE Pepscan Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
2. Pharsight Achieves First License Sale for Public-Source Database
3. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
4. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
5. Signalife Achieves $1.98 Million Sales Orders Thus Far
6. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
7. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
8. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
9. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
10. NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
11. BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Look inside ... hard-working items for the lab, from fluid handling to ... (GIS)—ready to ship when you order. , Preferred ... Pumps , from the L/S® model for precise flow ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... on researching,developing, manufacturing and marketing biopharmaceutical products,primarily ... filed with the Chinese,State Food and Drug ... IU,dosage formulation of EPIAO for the treatment ...
... of Business ... Development Activities -, LA JOLLA, Calif., Sept. ... it will transition from a,discovery and development company to a development-only ... will,streamline operations through the shut down of its discovery operations,and seek ...
... Cells and Other ... Development Programs, ROCKVILLE, Md., ... immunotherapeutics to treat,autoimmune disorders, cancer and infectious diseases, today announced that,it ... led by,Nextech Venture, included additional new investors Arcus Ventures, Innovis,Investments and ...
Cached Biology Technology:3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 23SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 2TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 4MacroGenics Raises $25M in Series D-2 Financing 2MacroGenics Raises $25M in Series D-2 Financing 3MacroGenics Raises $25M in Series D-2 Financing 4
(Date:7/9/2014)... era of increasing concern about the prevalence of ... a promising new pathway to disabling disease: blocking ... The scientists showed how bacterial siderophore, a small ... to fan bacterial growth as well as ... this infection process. Their findings appear in a ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
(Date:7/9/2014)... accrue. To completely and systematically archive this body ... researchers in the life sciences spend a quarter ... online survey of 70 people working in biology ... Information Technology FIT in Sankt Augustin. Many of ... or structured approach to data collection in their ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
... Traffic accidents involving wildlife are on the rise in Europe. ... be useful for increasing safety and preventing human and animal ... researchers have established at what time, on what day of ... roe deer are most likely to take place. Car ...
... that cancerous tumors grow collections of abnormal blood cells, the ... new evidence in an animal model suggests that blood vessels ... same purposeand could provide the key to a new way ... L. Makey, Edmund Chinchar, Carissa Howie, and Lucio Miele, all ...
... Animal sanctuaries can play an important role in rehabilitating goats ... scientists at Queen Mary, University of London. In ... moods in 18 goats, nine of which had endured poor ... shelter before arriving at a sanctuary. They created a spatial ...
Cached Biology News:Roe deer more likely to be run over at nightfall on a Sunday in April 2Drug reduces fat by blocking blood vessels 2Drug reduces fat by blocking blood vessels 3Rescue me: New study finds animals do recover from neglect 2
Tube-O-DIALYZER Floats, small....
Feline Rhinotracheitis Virus...
Ezrin/Radixin/Moesin Antibody...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: